What is reference pricing?

If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,
Since 2011, 7 new laws were added to AMNOG to dictate the early benefit assessment of drugs. Therefore, it is often called
The AMNOG law dictates that every pharmaceutical product with a new chemical entity which received its marketing authorization on or after 1
Ever wondered if patients influence the G-BA decision-making?